Citations

Clear

4610 citation(s) found for "Lu, Brian".

Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease
Feagan, Brian, D’Haens, Geert , Pai, Rish K. , Protić, Marijana , Escobar, Rodrigo , Reinisch, Walter, Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Hisamatsu, T, Hon, Kam‐Lun Ellis , Owen, C, Reinisch, Walter , Siegmund, Britta

Mayo Clinic

Zeitschrift für Gastroenterologie | September 4, 2025 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1810728 Get It

Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
Polites, Stephanie F. , Aldrink, Jennifer H. , Lautz, Timothy B. , Malek, Marcus M. , Fleming, Andrew M. , Roach, Jonathan P. , Radhakrishnan, Sridharan, Piché, Nelson , Osman, Yasmin, Lovvorn, Harold N. , Favela, Juan , Marquart, John , Craig, Brian T. , Seemann, Natashia M. , Petroze, Robin T. , Rich, Barrie S. , Glick, Richard D. , Selesner, Leigh , Fialkowski, Elizabeth , Boehmer, Chloé , Malek, Marcus M , Reiter, Audra , Murphy, Andrew J , Kastenberg, Zachary J , Tracy, Elisabeth T , Seemann, Natashia M , Rich, Barrie S , Fialkowski, Elizabeth A , Lautz, Timothy , Aldrink, Jennifer H , Vierkant, Robert A. , Chen, Stephanie , Kim, Eugene S. , Rinehardt, Hannah , Murphy, Andrew J. , Radhakrishnan, Sridharan, Kastenberg, Zachary J. , Tracy, Elisabeth T. , Le, Hau D. , Lal, Dave R. , Yoo, Ashley , Brown, Erin G. , Dasgupta, Roshni , Langham, Max Raymond

Mayo Clinic

Pediatric Blood & Cancer | September 3, 2025 | Volume: 72 | Issue: 12 | Pages: No page available

10.1002/pbc.32029 | PMID 40899404 Get It

ABSTRACT Introduction Children with hepatoblastoma (HB) and other solid tumors frequently undergo intraoperative blood transfusion (IBT) with unknown impact on oncologic outcomes and scant data to guide transfusion in this population. This study tested the hypothesis that IBT is associated with poorer survival in children with HB. Methods A multicenter retrospective observational study of patients aged <18 years with HB who underwent primary tumor resection, including liver transplantation, from 2010 to 2019 was performed at 19 institutions. The association of IBT with risk of recurrence and death were determined using propensity score reweighted (PSR) Cox proportional hazards regression analyses. Results There were 338 patients identified who met inclusion criteria and had sufficient data for inclusion. Of those, 257 (76%) received IBT, including 253 (98%) who received packed red blood cells (pRBC), 84 (33%) who received plasma, and 28 (11%) who received platelets. IBT was associated with higher pretreatment extent of disease ( p < 0.001), presence of annotation factors (+VPEFR: 50%, n = 129 vs. 37%, n = 30, p = 0.035), and complex resections (extended, meso‐, or total hepatectomy: 54%, n = 139 vs. 27%, n = 22, p < 0.001); these differences were mitigated after applying propensity score weighting. Patients who received IBT had greater postoperative hemoglobin (g/dL) (median 10 (I8–11) vs. 9 (8–10), p = 0.013) and required more postoperative plasma and platelet transfusions ( p < 0.05). Median follow‐up was 4.4 (2.0–8.3) years. Compared with non‐IBT patients, those with IBT had higher incidence of death (PSR HR 2.35, 95% CI 1.10–5.02). Recurrence did not significantly differ across groups (PSR HR = 0.82, 95% CI 0.45–1.48). Conclusion IBT was associated with greater hazard of death. Postoperative hemoglobin levels suggested that unnecessary transfusions occurred and a pRBC‐focused approach to IBT led to coagulopathy. Development of optimal transfusion strategies for HB are needed to minimize unnecessary transfusions.
Palliative Care Resource Utilization in Patients With Prion Disease
Zayat, Roaa , Piura, Yoav , Appleby, Brian S. , Robinson, Maisha T. , Day, Gregory S. , Day, Gregory S , Appleby, Brian

Mayo Clinic

Neurology | September 2, 2025 | Volume: 105 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000214076 | PMID 40893060 Get It

Contemporary genitourinary fistula management: treatment, trends, and innovations
Wei, Nancy , Pfeuti, Courtney K. , Linder, Brian J. , Wei, Nancy , Pfeuti, Courtney, Linder, Brian J , Wei, Nancy , Wei, Nancy

Mayo Clinic

Current Opinion in Obstetrics & Gynecology | September 2, 2025 | Volume: 37 | Issue: 6 | Pages: 432-437

10.1097/gco.0000000000001065 | PMID 40891591 Get It

Purpose of review To synthesize the current literature regarding the evaluation and management of genitourinary fistula in women. Recent findings Genitourinary fistula are aberrant communications between the urinary tract and genital tract that present with urinary leakage per the vagina. Initial management often involves conservative measures, such as urethral catheter or ureteral stent placement, progressing to surgical repair when needed. Key surgical principles include a tension-free, watertight closure with well-vascularized tissue including tissue interposition as appropriate, and postoperative urinary drainage. When surgical management of vesicovaginal fistula is necessary, a transvaginal repair is the most common. Other minimally invasive approaches are increasing and result in similarly high success rates with lower patient morbidity compared to open abdominal surgeries. The initial management of ureterovaginal fistula commonly includes ureteral stent placement. When not feasible or in persistent fistula, laparoscopic and robotic surgical repair with ureteral reconstruction offers high success rates with lower morbidity than an open approach. Summary Successful management of genitourinary fistula ranges from conservative urinary tract drainage to surgical interventions based on etiology, location, and complexity. Approaches to repair are shifting toward less invasive procedures. With optimal technique and surgical planning, high success rates can be achieved, particularly in primary repairs.
SEA CDM: Study-Experiment-Assay Common Data Model and Databases for Cross-Domain Data Integration and Analysis
Huffman, Anthony , Yeh, Feng-Yu , Hur, Junguk , Wu, Guanming, Athey, Brian, Zheng, Jie , Masci, Anna Maria , Wu, Guanming, Tao, Cui , Athey, Brian, He, Yongqun

Mayo Clinic

No container title available | August 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.26.671804 | PMID 40909744 Get It

Abstract With the increasing volume of biomedical experimental data, standardizing, sharing, and integrating heterogeneous experimental data across domains has become a major challenge. To address this challenge, we have developed an ontology-supported Study-Experiment-Assay (SEA) common data model (CDM), which includes 10 core and 3 auxiliary classes based on object-oriented modeling. SEA CDM uses interoperable ontologies for data standardization and knowledge inference. Building on the SEA CDM, we developed the Ontology-based SEA Network (OSEAN) relational database and knowledge graph, along with a set of ETL (Extract, Transform, Load) and query tools, and further applied them to represent 1,278 immune studies with over two million samples from three resources: VIGET, ImmPort, and CELLxGENE. Using simple, robust queries and analyses, our research identified multiple scientific insights into sex-specific immune responses, such as neutrophil degranulation and TNF binding to physiological receptors, following live attenuated and trivalent inactivated influenza vaccination. The novel SEA CDM system lays a foundation for establishing an integrative biodata ecosystem across biological and biomedical domains.
Outcomes Associated With SGLT2 Inhibitor Use Following Acute Myocardial Infarction Without Heart Failure: A Propensity-Matched Study
Issa, Rochell , Calcagno, Tess , Canova, Tyler , Issa, Ryan, Menon, Venu , Griffin, Brian P. , Kwon, Deborah , Wang, Tom Kai Ming , Wang, Tom Kai Ming , Kaelber, David C. , Tang, W.H. Wilson

Mayo Clinic

Angiology | August 25, 2025 | Volume: 77 | Issue: 6 | Pages: 704-713

10.1177/00033197251365016 | PMID 40852947 Get It

This retrospective propensity-matched cohort study assessed the association between sodium-glucose co-transporter-2 inhibitor (SGLT2i) use and cardiovascular outcomes in patients with acute myocardial infarction (AMI) without a history of heart failure. Using the TriNetX U.S. Collaborative Network, we identified 1440 matched patients (720 SGLT2i+ vs 720 SGLT2i−) with preserved ejection fraction and no prior heart failure. Nearly 90% of patients had diabetes. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of MI, stroke, heart failure, and all-cause mortality. At 1 year, MACE occurred in 17.4% of SGLT2i+ versus 22.0% of SGLT2i− patients (odds ratio [OR] 0.746, 95% CI 0.574-0.969; P = .028), and all-cause mortality occurred in 3.1% versus 7.6%, respectively (OR 0.389, 95% CI 0.234-0.645; P < .001). SGLT2i use was also associated with lower risks of major bleeding. Findings were consistent over long-term follow-up. While the observed associations suggest potential cardioprotective effects of SGLT2i post-MI in patients without heart failure, residual confounding cannot be excluded. The observed reduction in bleeding events is novel and warrants further investigation in prospective studies.
Intracardiac thrombosis and its management during liver transplantation: international, multicenter, case-control study
Prete, Luca Del , Cazzaniga, Beatrice , Aniskevich, Stephen , Agopian, Vatche G. , Smith, Natalie , Cacioppo, Brian J, Nuti, Anna Maria, Wang, Ryan , Gamboa, Bs Sophia, Groose, Molly K. , Sheth, Mansi, Cywiński, Jacek B. , Wray, Christopher , Hashimoto, Koji , Liu, Qiang , Quintini, Cristiano , Del Prete, Luca , Agopian, Vatche G , Smith, Natalie K , Tu, Chao , Groose, Molly K , Cywinski, Jacek B , Nguyen-Buckley, Christine , Florman, Sander S , Liu, Qiang , Ekser, Burcin , Aniskevich, Stephen , Cacioppo, Brian J., Watson, Christopher, Pai, Sher‐Lu , Nguyen, Christine , Florman, Sander , Croome, Kristopher P. , Ekser, Burcin

Mayo Clinic

International Journal of Surgery | August 22, 2025 | Volume: 111 | Issue: 12 | Pages: 8793-8805

10.1097/js9.0000000000002896 | PMID 40844270 Get It

Background: Intracardiac thrombosis (ICT) during liver transplantation (LT) is a rare but life-threatening complication with limited data regarding its risk factors, management, and outcomes. This study aimed to identify factors associated with ICT development, define predictors of intraoperative outcomes, and propose a novel classification and management algorithm for ICT. Methods: A multicenter, international retrospective case-control study was conducted on liver transplant recipients from seven centers between January 2005 and December 2023. ICT cases were identified through transesophageal echocardiography (TEE) or autopsy and matched 1:1 with controls. Results: Among 11 077 liver transplant recipients screened, 133 patients (1.2%) developed ICT. ICT occurred predominantly after reperfusion (58%). Compared to controls, ICT cases exhibited higher preoperative international normalized ratio ( P = 0.001) and fibrinogen levels ( P = 0.014). Post-reperfusion syndrome ( P < 0.001), disseminated intravascular coagulation ( P < 0.001), and primary graft failure ( P = 0.002) were also more common in the ICT group. Continuous veno-venous hemofiltration during surgery (odds ratio [OR] 8.20, 95% confidence interval [CI]: 2.09–38.1; P = 0.004) was associated with ICT development. ICT was associated with markedly higher rates of cardiac arrest ( P < 0.001) and intraoperative mortality ( P < 0.001), with thrombus location in the left heart chambers representing a significant predictor of mortality (OR 20.7, 95% CI: 6.25–81.3; P < 0.001). ICT grades 2 and 3 were associated with a markedly increased risk of intraoperative cardiac arrest ( P < 0.05). Importantly, delayed use of TEE was strongly associated with intraoperative death (OR 6.27, 95% CI: 1.45–27.1; P = 0.014). The 90-day mortality was 43% in ICT cases compared to 4.5% in controls, while 1-year mortality was 46% versus 10.5%, respectively. Conclusions: ICT during LT is a rare but severe complication associated with intraoperative mortality and poor short-term survival. Coagulation profile and intraoperative management play critical roles in ICT development. The early use of TEE enables timely diagnosis and intervention, improving patient outcomes. We propose a novel ICT classification offering a systematic framework for risk stratification and management to mitigate progression and mortality.
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Lurz, Philipp , Hahn, Rebecca T. , Kodali, Susheel , Makkar, Raj , Sharma, Rahul , Davidson, Charles J. , O’Neill, Brian , Yadav, Pradeep , Zahr, Firas , Chadderdon, Scott , Eleid, Mackram F. , Smith, Robert L, Garcia, Santiago , Kister, Tobias , Kipperman, Robert, Lim, Scott, Hermiller, James, Mishell, Jacob M. , Rassi, Andrew N., Szeto, Wilson Y. , Babaliaros, Vasilis , Barker, Colin M. , Summers, Matthew , Chetcuti, Stanley, Ailawadi, Gorav , Russo, Mark, Rinaldi, Michael, Chehab, Bassem , Nickenig, Georg, Stinis, Curtiss, Inglessis‐Azuaje, Ignacio , Dhoble, Abhijeet , Petrossian, George , Shah, Pinak, Staniloae, Cezar , Nores, Marcos, Singh, Gagan D. , Baldus, Stephan , Rudolph, Volker , Barb, Ilie, Klodell, C.T., Gray, William A. , Strote, Justin A, Sannino, Anna , Grayburn, Paul , Mack, Michael J. , Leon, Martin B. , Thourani, Vinod H. , Lim, D. Scott , Szerlip, Molly , Kister, Tobias , Lim, D Scott , Saxon, John , Kapadia, Samir , Mishell, Jacob M , Herrmann, Howard C , Hausleiter, Jörg , Babaliaros, Vasilis , Barker, Colin M , Lindman, Brian R , Latib, Azeem , von Bardeleben, Ralph Stephan , Summers, Matthew , Ailawadi, Gorav , Rinaldi, Michael , Chehab, Bassem M , Nickenig, Georg , Inglessis-Azuaje, Ignacio , Dhoble, Abhijeet , Chhatriwalla, Adnan K , Petrossian, George , Shah, Pinak , Staniloae, Cezar , Williams, Mathew , McCabe, James M , Singh, Gagan , Baldus, Stephan , Rudolph, Volker , Klodell, Charles , Gray, William , Strote, Justin , Sannino, Anna , Grayburn, Paul , Mack, Michael J , Thourani, Vinod H , Davidson, Charles J. , Hahn, Rebecca T , Lurz, Philipp , Smith, Robert L, Whisenant, Brian K. , Kapadia, Samir , Hausleiter, Jörg , Lindman, Brian R. , Latib, Azeem , Muhammad, Kamran I. , Williams, Mathew

Mayo Clinic

European Heart Journal | August 21, 2025 | Volume: 47 | Issue: 17 | Pages: 2059-2073

10.1093/eurheartj/ehaf676 | PMID 40878717 Get It

Abstract Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
A 5-Year Epidemiological Study of Monomicrobial Enterococcal Bloodstream Infection in a Population-Based Cohort
Bayless, David , Baddour, Larry M. , Lahr, Brian D. , Hagan, Grace , Cao, Jenny Jia Ling , DeSimone, Daniel C. , Bayless, David R , Hagan, Grace A , Cao, Jenny J , Baddour, Larry , DeSimone, Daniel C

Mayo Clinic

Open Forum Infectious Diseases | August 20, 2025 | Volume: 12 | Issue: 9 | Pages: No page available

10.1093/ofid/ofaf506 | PMID 40926878 Get It

Abstract Background The incidence, epidemiology, and clinical characteristics of enterococcal bloodstream infection (BSI) have not previously been studied on a population-based level in the United States. Methods We utilized the Expanded Rochester Epidemiology Project medical records linkage system to conduct a contemporary 5-year, retrospective, population-based study of monomicrobial enterococcal (ME) BSI among adult residents of 8 counties in southeast Minnesota from January 1, 2018 to December 31, 2022. Results A total of 109 cases of ME-BSI were identified. The overall age- and sex-adjusted incidence rate was 6.7 per 100 000 person-years (95% confidence interval, 5.4–7.9). Multivariable analysis revealed that male sex (P &lt; .001) and older age (P &lt; .001) were each independently associated with increased incidence, whereas no temporal association was demonstrated (year effect, P = .475). The median age of incident cases was 76.8 years (interquartile range, 65.0–83.3). Urinary tract source was the most common presumed source (42.2%), and Enterococcus faecalis was the predominant (83.5%) pathogen. Overall, 14.4% of patients met modified Duke criteria for definite infective endocarditis. Cumulative mortality was 28.4% at 12 weeks and 43.1% at 1 year. Conclusions In this population-based study, ME-BSI was significantly associated with older age and male sex. There was a high rate of mortality at 12 weeks and 1 year, with ∼1 out of 7 cases complicated by definite infective endocarditis. These findings underscore the importance of ongoing investigation of this syndrome.